STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD

STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD

Date: 2019-08-23 By Nikita Chaurasia

Atrium Spectrum Disorder (ASD) affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity.   Such technologies are used for ....

Fitbit to support Singapore’s public health and smart nation programs

Health population initiatives will be powered by Fitbit wearable devices and new Premium service Fitbit Inc., a San Francisco based tech company, has announced that it will partner with the Health Promotion Board (HPB) of Singapore for a h....

Spirit Banner & Ion Energy ink new business combination agreement

After the completion of the business combination, a Spirit Banner subsidiary will merge with Ion Energy and change its name to Ion Energy Holdings Inc.   The business combination will see Spirit Banner procure all outstanding and i....

Microsoft’s SMS Organizer for Android expands to UK, US and Australia

Leading software company Microsoft’s SMS Organizer app for the Android platform is reportedly available to users from the US, UK and Australia, according to XDA Developers. The app is designed to de-clutter smartphones by helping man....

South Korea’s KCGI is looking to acquire a stake in Asiana Airlines

Asiana Airlines is expecting to receive its initial bids in September accompanied by binding bids in October. Korea Corporate Governance Improvement (KCGI), South Korea’s activist fund and the second-largest stakeholder in the holdin....

U.S. representatives to discuss Facebooks’ Libra with Swiss authorities

U.S. House of Representatives will discuss its concern on cryptocurrency with FDPIC (Federal Data Protection and Information Commissioner) Adrian Lobsiger.   The discussion will mainly involve Facebook’s soon to be launched L....

Mallinckrodt states positive results of Terlipressin in HRS-1 patients

The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1. The study verified HRS-1 reversal along with other 3 components-renal function enhancement, escaping dialysis, and shor....